Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$8.46 +0.2%	$9.29	$7.35 ▼ $13.70	$2.55B	0.11	364,969 shs	158,504 shs
AMLX Amylyx Pharmaceuticals	$7.64 -2.6%	$6.79	$1.77 ▼ $8.72	$681.04M	-0.46	1.32 million shs	880,307 shs
IMVT Immunovant	$15.46 -1.7%	$16.55	$12.72 ▼ $34.47	$2.64B	0.66	1.31 million shs	646,798 shs
RARE Ultragenyx Pharmaceutical	$27.54 -1.0%	$33.32	$25.81 ▼ $60.37	$2.65B	0.25	2.81 million shs	1.53 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	0.00%	-3.75%	-3.09%	-12.60%	-23.16%
AMLX Amylyx Pharmaceuticals	0.00%	-1.04%	+3.38%	+65.73%	+306.38%
IMVT Immunovant	0.00%	-1.59%	-11.66%	+10.27%	-42.70%
RARE Ultragenyx Pharmaceutical	0.00%	-3.16%	-11.25%	-21.67%	-43.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALVO Alvotech	2.8472 of 5 stars	3.5	4.0	0.0	1.1	0.0	1.9
AMLX Amylyx Pharmaceuticals	2.8184 of 5 stars	4.5	1.0	0.0	1.0	2.5	0.6
IMVT Immunovant	1.5383 of 5 stars	3.4	0.0	0.0	2.9	1.7	0.0
RARE Ultragenyx Pharmaceutical	4.3872 of 5 stars	4.5	1.0	3.8	2.9	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVO Alvotech	3.00	Buy	$14.00	65.48% Upside
AMLX Amylyx Pharmaceuticals	3.00	Buy	$11.75	53.80% Upside
IMVT Immunovant	2.80	Moderate Buy	$35.33	128.55% Upside
RARE Ultragenyx Pharmaceutical	2.92	Moderate Buy	$81.50	195.93% Upside

Current Analyst Ratings Breakdown

Latest AMLX, RARE, IMVT, and ALVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	RARE Ultragenyx Pharmaceutical	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$136.00 ➝ $128.00
8/6/2025	RARE Ultragenyx Pharmaceutical	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$112.00 ➝ $105.00
7/28/2025	IMVT Immunovant	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$17.00 ➝ $18.00
7/28/2025	RARE Ultragenyx Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$80.00
7/18/2025	ALVO Alvotech	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $14.00
7/14/2025	RARE Ultragenyx Pharmaceutical	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$35.00 ➝ $34.00
7/14/2025	RARE Ultragenyx Pharmaceutical	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$65.00 ➝ $55.00
7/10/2025	AMLX Amylyx Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$10.00
7/10/2025	IMVT Immunovant	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold	$18.00
7/10/2025	RARE Ultragenyx Pharmaceutical	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$88.00 ➝ $65.00
6/24/2025	AMLX Amylyx Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold

(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVO Alvotech	$491.98M	5.18	N/A	N/A	($1.37) per share	-6.18
AMLX Amylyx Pharmaceuticals	$87.37M	7.79	N/A	N/A	$2.40 per share	3.18
IMVT Immunovant	N/A	N/A	N/A	N/A	$4.16 per share	N/A
RARE Ultragenyx Pharmaceutical	$610.16M	4.35	N/A	N/A	$1.57 per share	17.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVO Alvotech	-$231.86M	$0.37	22.86	42.30	N/A	16.42%	-36.37%	12.70%	8/13/2025 (Estimated)
AMLX Amylyx Pharmaceuticals	-$301.74M	-$3.11	N/A	N/A	N/A	N/A	-80.33%	-68.03%	N/A
IMVT Immunovant	-$413.84M	-$2.74	N/A	N/A	N/A	N/A	-80.60%	-71.89%	8/12/2025 (Estimated)
RARE Ultragenyx Pharmaceutical	-$569.18M	-$5.53	N/A	N/A	N/A	-87.34%	-237.48%	-37.66%	N/A

Latest AMLX, RARE, IMVT, and ALVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ALVO Alvotech	-$0.06	N/A	N/A	N/A	$120.51 million	N/A
8/12/2025	Q1 2026	IMVT Immunovant	-$0.69	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	AMLX Amylyx Pharmaceuticals	-$0.44	-$0.46	-$0.02	-$0.46	N/A	N/A
8/5/2025	Q2 2025	RARE Ultragenyx Pharmaceutical	-$1.27	-$1.17	+$0.10	-$1.17	$161.37 million	$166.50 million
5/29/2025	Q4 2025	IMVT Immunovant	-$0.72	-$0.64	+$0.08	-$0.64	N/A	$0.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVO Alvotech	N/A	1.73	1.19
AMLX Amylyx Pharmaceuticals	N/A	12.05	12.05
IMVT Immunovant	N/A	11.16	11.16
RARE Ultragenyx Pharmaceutical	N/A	2.45	2.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVO Alvotech	N/A
AMLX Amylyx Pharmaceuticals	95.84%
IMVT Immunovant	47.08%
RARE Ultragenyx Pharmaceutical	97.67%

Insider Ownership

Company	Insider Ownership
ALVO Alvotech	0.46%
AMLX Amylyx Pharmaceuticals	11.70%
IMVT Immunovant	1.80%
RARE Ultragenyx Pharmaceutical	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVO Alvotech	1,032	301.48 million	300.10 million	Not Optionable
AMLX Amylyx Pharmaceuticals	200	89.14 million	78.71 million	Optionable
IMVT Immunovant	120	171.07 million	167.99 million	Optionable
RARE Ultragenyx Pharmaceutical	1,294	96.37 million	91.07 million	Optionable

AMLX, RARE, IMVT, and ALVO Headlines

Recent News About These Companies

HC Wainwright Issues Optimistic Forecast for RARE Earnings

2 hours ago | americanbankingnews.com

What is William Blair's Estimate for RARE Q3 Earnings?

2 hours ago | americanbankingnews.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pacira Pharmaceuticals (PCRX), Ultragenyx Pharmaceutical (RARE) and MoonLake Immunotherapeutics (MLTX)

August 9 at 9:09 PM | theglobeandmail.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

August 9 at 12:25 PM | globenewswire.com

What is Wedbush's Estimate for RARE FY2028 Earnings?

August 9 at 11:44 AM | marketbeat.com

Cantor Fitzgerald Brokers Cut Earnings Estimates for RARE

August 9 at 9:28 AM | marketbeat.com

HC Wainwright Issues Positive Estimate for RARE Earnings

August 9 at 8:09 AM | marketbeat.com

Leerink Partnrs Has Positive Estimate for RARE Q3 Earnings

August 9 at 8:09 AM | marketbeat.com

What is William Blair's Forecast for RARE Q3 Earnings?

August 9 at 8:09 AM | marketbeat.com

Cantor Fitzgerald Issues Negative Outlook for RARE Earnings

August 9 at 3:19 AM | americanbankingnews.com

Ultragenyx (RARE) Q2 Revenue Up 13%

August 9 at 2:46 AM | theglobeandmail.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

August 9 at 2:46 AM | finance.yahoo.com

Leerink Partnrs Has Positive Outlook of RARE Q3 Earnings

August 9 at 2:25 AM | americanbankingnews.com

William Blair Brokers Lower Earnings Estimates for RARE

August 8 at 9:58 AM | marketbeat.com

What is Leerink Partnrs' Forecast for RARE Q1 Earnings?

August 8 at 9:36 AM | marketbeat.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $105.00 Price Target at Cantor Fitzgerald

August 7 at 10:56 AM | marketbeat.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2025 Earnings Call Transcript

August 7 at 8:30 AM | msn.com

Ultragenyx Q2 sales up 13%, loss narrows

August 6, 2025 | pressdemocrat.comP

2RARE : 8 Analysts Assess Ultragenyx Pharmaceutical: What You Need To Know

August 6, 2025 | benzinga.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Releases Quarterly Earnings Results, Beats Estimates By $0.10 EPS

August 6, 2025 | marketbeat.com

Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y

August 6, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
Why the American Eagle Stock Rally Isn't Just Speculation
By Gabriel Osorio-Mazilli | July 28, 2025
View Why the American Eagle Stock Rally Isn't Just Speculation
These 3 Rare Earth Stocks Are Surging Alongside MP Materials
By Leo Miller | July 19, 2025
View These 3 Rare Earth Stocks Are Surging Alongside MP Materials
NVIDIA: A Major Indicator Just Flashed Sell, But Should You?
By Sam Quirke | July 30, 2025
View NVIDIA: A Major Indicator Just Flashed Sell, But Should You?
MP Materials Stock Booms on New Government Positioning
By Gabriel Osorio-Mazilli | July 14, 2025
View MP Materials Stock Booms on New Government Positioning

AMLX, RARE, IMVT, and ALVO Company Descriptions

Alvotech NASDAQ:ALVO

$8.46 +0.02 (+0.24%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$8.46 0.00 (0.00%)

As of 08/8/2025 04:10 PM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Amylyx Pharmaceuticals NASDAQ:AMLX

$7.64 -0.20 (-2.55%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$7.58 -0.06 (-0.85%)

As of 08/8/2025 05:42 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Immunovant NASDAQ:IMVT

$15.46 -0.27 (-1.72%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$16.32 +0.86 (+5.56%)

As of 08/8/2025 07:35 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Ultragenyx Pharmaceutical NASDAQ:RARE

$27.54 -0.29 (-1.04%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$27.56 +0.02 (+0.05%)

As of 08/8/2025 05:21 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time